Molbio Diagnostics shares have surged nearly 30% in two sessions, extending their post-listing gains to around 80% from the IPO price. The sharp rally comes as the newly listed company reported a strong Q1 FY27 performance, swinging to a profit of Rs 58.75 crore from a loss in the year-ago quarter.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.